Performance of HPV E6/E7 mRNA assay as primary screening test: Results from the NTCC2 trial
暂无分享,去创建一个
A. Del Mistro | A. Gillio-Tos | L. De Marco | G. Ronco | P. Giorgi Rossi | M. Confortini | E. Allia | A. Iossa | A. Barca | F. Carozzi | L. Bonvicini | F. Venturelli | P. Mancuso | M. Benevolo | H. Frayle | S. Bisanzi | D. Gustinucci | S. Bulletti | E. Cesarini | Laura Toniolo | S. Gori | B. Passamonti | Raffaella Rizzolo | Anna Gillio-Tos | Laura Bonvicini
[1] M. Schiffman,et al. Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, Journal of lower genital tract disease.
[2] E. Franco,et al. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus result. , 2021, American journal of obstetrics and gynecology.
[3] A. Del Mistro,et al. p16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. , 2020, Journal of the National Cancer Institute.
[4] M. Rugge,et al. Risk of CIN2 or more severe lesions after negative HPV‐mRNA E6/E7 overexpression assay and after negative HPV‐DNA test: Concurrent cohorts with a 5‐year follow‐up , 2020, International journal of cancer.
[5] M. Schiffman,et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.
[6] C. Dombrowski,et al. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation , 2020, BMJ Open.
[7] P. Giorgi Rossi,et al. Interlaboratory concordance of p16/Ki‐67 dual‐staining interpretation in HPV‐positive women in a screening population , 2020, Cancer cytopathology.
[8] T. Abebe,et al. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review , 2019, Infectious Agents and Cancer.
[9] C. Borgfeldt,et al. Population-based primary HPV mRNA cervical screening compared with cytology screening. , 2019, Preventive medicine.
[10] M. Schiffman,et al. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program , 2019, JAMA internal medicine.
[11] M. Schiffman,et al. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women , 2019, JAMA oncology.
[12] L. Kostrikis,et al. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing , 2018, Viruses.
[13] E. Franco,et al. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[14] D. Wallwiener,et al. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany , 2018, Journal of Clinical Microbiology.
[15] J. Dillner,et al. HPV‐mRNA and HPV‐DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri , 2018, International journal of cancer.
[16] S. Franceschi,et al. Eurogin roadmap 2017: Triage strategies for the management of HPV‐positive women in cervical screening programs , 2018, International journal of cancer.
[17] J. Chorny,et al. Human papillomavirus detection with genotyping by the cobas and Aptima assays: Significant differences in HPV 16 detection? , 2018, Diagnostic cytopathology.
[18] Nancy Santesso,et al. Cytology versus HPV testing for cervical cancer screening in the general population. , 2017, The Cochrane database of systematic reviews.
[19] E. Franco,et al. Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[20] A. Del Mistro,et al. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types , 2017, Journal of Clinical Microbiology.
[21] M. Zorzi,et al. Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program , 2016, British Journal of Cancer.
[22] M. Schiffman,et al. Triage of HPV positive women in cervical cancer screening. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[23] T. Iftner,et al. A review of the clinical performance of the Aptima HPV assay. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[24] E. Lynge,et al. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above , 2016, PloS one.
[25] J. Cuzick,et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. , 2015, American journal of clinical pathology.
[26] P. Sasieni,et al. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany , 2015, Journal of Clinical Microbiology.
[27] Clare Gilham,et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.
[28] E. Lynge,et al. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay. , 2013, The Journal of molecular diagnostics : JMD.
[29] J. Berkhof,et al. The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening , 2013, Journal of Clinical Microbiology.
[30] J. Belinson,et al. Primary Cervical Cancer Screening and Triage Using an mRNA Human Papillomavirus Assay and Visual Inspection , 2013, International Journal of Gynecologic Cancer.
[31] J. Cuzick,et al. Comparing the performance of six human papillomavirus tests in a screening population , 2013, British Journal of Cancer.
[32] J. Cuzick,et al. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. , 2012, Epidemiologia e prevenzione.
[33] M. Schiffman,et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012, CA: a cancer journal for clinicians.
[34] M. Hudgens,et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study , 2011, International journal of cancer.
[35] P. Ghatage,et al. Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer , 2010, Journal of Clinical Microbiology.
[36] Y. Liu,et al. Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening: The Shenzhen Cervical Cancer Screening Trial I , 2010, International Journal of Gynecologic Cancer.
[37] Joakim Dillner,et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.
[38] Mark Sherman,et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.
[39] Hagerstoten. American society for colposcopy and cervical pathology. , 1999, Journal of lower genital tract disease.